GPER1 and endometrial cancer: In the present study, we demonstrated that treatment of estradiol (E2), G1 (a GPR30 agonist) and tamoxifen (4-hydroxytamoxifen, OHT) induced phosphorylation of FAK at Y397 and cell migration in endometrial cancer cell lines.